Video (download) Kazantseva Antonina1, Tatyana Yakovleva2, Elena Makarova3, Nadezhda Kriklivaya4, Nadezhda Bazhan51ICG SB RAS, Novosibirsk, Russia, antonyna@yandex.ru2ICG SB RAS, Novosibirsk, Russia, tatyanajakovleva@yandex.ru3ICG SB RAS, Novosibirsk, Russia, enmakarova@gmail.com4ICG SB RAS, Novosibirsk, Russia, nad.krikl@mail.ru5ICG SB RAS, Novosibirsk, Russia, bazhan-nm@yandex.ru Postmenopausal women have an increased risk of the development of the metabolic syndrome and type 2 diabetes. In pharmacological experiments it was found that hepatic hormone fibroblast growth factor 21 (FGF21) acts as a potent metabolic regulator. But the normalizing metabolic effects of FGF21 have been described only for males. Ovariectomized female mice may be considered as a model of decreased levels of estradiol in women during postmenopause. In this study we investigated the pharmacological effects of recombinant FGF21 in ovariectomized female mice. Ovariectomized animals received daily FGF21 injections (1 mkg/g body weight) for 7 days. On the 7th day, mice were tested in a glucose tolerance test. Then in mice blood levels of insulin, glucose and adiponectin were determined. Our results showed that FGF21 did not reduce body weight and adiposity, but improved carbohydrate lipid metabolism in estrogen-deficient female mice. These data allow considering FGF21 as a potential regulator for the correction of metabolic syndrome caused by a lack of estrogen in female mice.

Read More